“NOXCOVID European study is continuing to proceed as planned, with the Company announcing the encouraging initial safety data review of the first two dosages (ASX announcement 5 November 2020). Cohorts 3 and 4 are now fully enrolled and the Company anticipates issuing the next data review in early January 2021. With the pandemic reaching new heights in Europe, other hospitals in other European countries are now preparing to join the NOXCOVID trial.”
Nice to have the recent silence broken on NOXCOVID the statement seems to have bullish sentiment given the expansion to other hospitals.
- Forums
- ASX - By Stock
- NOX
- Ann: Federal Government Approved Future Overseas R&D Expenditure
Ann: Federal Government Approved Future Overseas R&D Expenditure, page-2
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
MND
Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?
IGO
IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity
Add NOX (ASX) to my watchlist
|
|||||
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.04M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 72463 | 6.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.2¢ | 8810 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 72463 | 0.069 |
3 | 22705 | 0.068 |
1 | 1672 | 0.066 |
1 | 15000 | 0.065 |
1 | 15626 | 0.064 |
Price($) | Vol. | No. |
---|---|---|
0.072 | 8810 | 1 |
0.073 | 74991 | 2 |
0.074 | 50000 | 1 |
0.076 | 4999 | 1 |
0.079 | 12000 | 1 |
Last trade - 10.16am 29/07/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
Day chart unavailable